UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_______________________________
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): May 21,
2008
Immunomedics,
Inc.
(Exact Name
of Registrant as Specified in Charter)
|
Delaware
|
000-12104
|
61-1009366
|
|
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
300
American Road, Morris Plains, New Jersey
|
07950
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
|
(973)
605-8200
|
|
(Registrant's
telephone number,
including
area code)
|
|
|
|
Not
applicable
(Former
Name or Former Address, if Changed Since Last Report)
|
|
|
Check the
appropriate box below if the Form 8-K is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following
provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425).
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12).
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b)).
[
] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)).
Item
8.01. Other
Events.
On May 21,
2008, Immunomedics, Inc., a Delaware corporation (the “Company”), received $6.0
million from the sale of two auction rate securities at par value plus accrued
interest. The Company continues to hold six auction rate securities
with par value of $23 million in the aggregate. The Company does not
intend to hold its remaining auction rate securities to maturity, and will
continue to monitor transactions in the auction rate securities market for
possible liquidation on terms that are acceptable for the Company.
SIGNATURES
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
IMMUNOMEDICS,
INC.
By: /s/ Cynthia L.
Sullivan
Name:Cynthia
L. Sullivan
Title:President
and Chief Executive Officer
Date: May
22, 2008